Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity
This article was originally published in The Pink Sheet Daily
Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.
You may also be interested in...
Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.
Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.